Phaseline

Companies › Leadiant Biosciences

Leadiant Biosciences: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 2; Neurology, Genitourinary.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ManNAc (N-acetyl-D-mannosamine monohydrate)
Precursor for N-acetylneuraminic acid (Neu5Ac) biosynthesis; restores glycan sialylation i
GNEPhase 2GNE Myopathy; Focal Segmental Glomerulosclerosis–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04231266ManNAc (N-acetyl-D-mannosamine monohydrate)Phase 2GNE MyopathyNeurologyJun 2025
NCT06664814ManNAc (N-acetyl-D-mannosamine monohydrate)Phase 2Focal Segmental GlomerulosclerosisGenitourinaryNov 2030

Targets

GNE (1)

Companies with the same targets

–

Companies built like this

Woolsey Pharmaceuticals Actinogen Medical Abrexa Pharmaceuticals Neuron23 Bial R&D Investments

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.